Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.51 CAD | 0.00% | +0.12% | -7.70% |
Apr. 22 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
Apr. 01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.70% | 72.15M | - | - | |
+25.83% | 661B | C+ | ||
+27.00% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+13.09% | 231B | B+ | ||
+5.46% | 200B | B- | ||
-9.61% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- RX Stock
- Ratings BioSyent Inc.